Melanocytic Neoplasm

In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. Four mutations involving the MAP2K2 gene… (full text at CIViC)

PMID 24265153 · Van Allen et al., 2014 · Open in CIViC

In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. Four mutations involving the MAP2K2 gene… (full text at CIViC)

PMID 24265153 · Van Allen et al., 2014 · Open in CIViC

In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. Four mutations involving the MAP2K2 gene… (full text at CIViC)

PMID 24265153 · Van Allen et al., 2014 · Open in CIViC

In a cohort of 42 metastatic uveal melanoma patients treated with PD-1 inhibition, only one responded. A germline frameshift mutation in MBD4 was identified in this responder patient, with somatic los… (full text at CIViC)

PMID 29760383 · Rodrigues et al., 2018 · Open in CIViC

Highest MERTK expression was observed in metastatic melanomas, followed by primary melanomas, and lowest in benign nevi. Over half of melanoma cell lines overexpressed MERTK compared with normal human… (full text at CIViC)

PMID 23585477 · Schlegel et al., 2013 · Open in CIViC

c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro. GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation. SiR… (full text at CIViC)

PMID 24140933 · Surriga et al., 2013 · Open in CIViC

Preclinical study in uveal melanoma cell lines. c-MET was identified as a transcriptional target of miR-144. miR-144 was downregulated in 4 uveal melanoma cell lines and 5 human uveal melanoma tumor t… (full text at CIViC)

PMID 25961751 · Sun et al., 2015 · Open in CIViC

A patient with recurrent melanoma harboring a MIPOL1-RAF1 fusion with an intact RAF1 kinase domain received belvarafenib after progression following pembrolizumab with radiotherapy. Belvarafenib was i… (full text at CIViC)

PMID 38470950 · Kim et al., 2024 · Open in CIViC

In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. In one patient relapse-associated focal … (full text at CIViC)

PMID 24265153 · Van Allen et al., 2014 · Open in CIViC

Preliminary analysis of biopsies from BRAF(V600E) melanoma patients revealed that phosphorylated (active) CREB was suppressed by RAF-MEK inhibition but restored in relapsing tumours. Expression of tra… (full text at CIViC)

PMID 24185007 · Johannessen et al., 2013 · Open in CIViC

In a cell line with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth.

PMID 26490311 · Kong et al., 2016 · Open in CIViC

In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth.

PMID 26490311 · Kong et al., 2016 · Open in CIViC

Median overall survival of patients with nonsynonymous mutations in mTOR was shorter.

PMID 26490311 · Kong et al., 2016 · Open in CIViC

In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth.

PMID 26490311 · Kong et al., 2016 · Open in CIViC

Loss-of-function of NF1, a tumor suppressor and negative regulator of RAS signaling, is recurrent in melanoma and contributes to MAPK pathway activation. This study demonstrates that NF1 loss in melan… (full text at CIViC)

PMID 40494652 · Ibrahim et al., 2025 · Open in CIViC

Taken together with preclinical studies in the mouse model and genetic studies in human melanoma cell lines, these observations further support the hypothesis that NF1/neurofibromin suppression may pl… (full text at CIViC)

PMID 23171796 · Maertens et al., 2013 · Open in CIViC

Preclinical study of mouse melanoma both in-vitro and in-vivo. Braf/Nf1-mutant melanomas were less sensitive to vemurafenib than the MEK inhibitor PD0325901. mTOR inhibition with rapamycin had a more … (full text at CIViC)

PMID 23171796 · Maertens et al., 2013 · Open in CIViC

NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. Knockdown of NF1 led to PLX4720 resistance in-vitro. MEK inhibition with AZD6244 (se… (full text at CIViC)

PMID 23288408 · Whittaker et al., 2013 · Open in CIViC

In NF1 Q1336*-mutant MeWo melanoma cells, NST-628 showed potent antiproliferative activity, increased apoptosis, and durably reduced MAPK-pathway signaling. In intracranial MeWo-luc xenografts, once-d… (full text at CIViC)

PMID 38588399 · Ryan et al., 2024 · Open in CIViC

In a retrospective study of four relapsed, malignant melanoma patients, NF1 R2450* mutation was associated with acquired resistance to vemurafenib monotherapy in one patient.

PMID 23288408 · Whittaker et al., 2013 · Open in CIViC

In a retrospective cohort of 657 patients with melanoma, 92 (14.0%) had NRAS copy-number gain (>2 copies). Patients with NRAS gain had shorter median overall survival than patients with normal NRAS co… (full text at CIViC)

PMID 29245078 · Yan et al., 2018 · Open in CIViC

A patient with melanoma harboring NRAS G12A received belvarafenib monotherapy after two prior lines of systemic therapy and achieved a partial response as the best RECIST response. Belvarafenib treatm… (full text at CIViC)

PMID 38470950 · Kim et al., 2024 · Open in CIViC

Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mu… (full text at CIViC)

PMID 18375819 · Banerji et al., 2008 · Open in CIViC

A patient with acral melanoma harboring NRAS G13R received belvarafenib monotherapy after four prior lines of systemic therapy and achieved stable disease as the best RECIST response. The patient rece… (full text at CIViC)

PMID 38470950 · Kim et al., 2024 · Open in CIViC

In a retrospective study of 30 metastatic melanoma patients, a patient harboring NRAS G13R mutation was reported to be resistant to vemurafenib treatment. The patient was initially found to harbor a B… (full text at CIViC)

PMID 24463458 · Rizos et al., 2014 · Open in CIViC

In a retrospective cohort of 657 patients with melanoma, 92 (14.0%) had NRAS copy-number gain (>2 copies). Patients with NRAS gain had shorter median overall survival than patients with normal NRAS co… (full text at CIViC)

PMID 29245078 · Yan et al., 2018 · Open in CIViC

In melanoma preclinical models, increased NRAS expression enhanced sensitivity to binimetinib in NRAS-copy-normal A875 cells, whereas NRAS knockdown decreased binimetinib sensitivity in NRAS-gain WM26… (full text at CIViC)

PMID 29245078 · Yan et al., 2018 · Open in CIViC

In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS.

PMID 22180178 · Jakob et al., 2012 · Open in CIViC

Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growt… (full text at CIViC)

PMID 24950457 · Fedorenko et al., 2014 · Open in CIViC

Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk.

PMID 23861977 · Tschandl et al., 2013 · Open in CIViC

Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation. 71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9… (full text at CIViC)

PMID 23414587 · Ascierto et al., 2013 · Open in CIViC

A patient with melanoma harboring NRAS Q61H received belvarafenib monotherapy after two prior lines of systemic therapy and had progressive disease as the best RECIST response. The patient received be… (full text at CIViC)

PMID 38470950 · Kim et al., 2024 · Open in CIViC